Thermogenesis

Heute möchte ich euch einen,meiner Meinung nach, hochinteressanten,sehr günstig bewerteten Stem Cell Player Thermogenesis (Nasdaq:KOOL) vorstellen:

THERMOGENESIS Corp. designs, develops, manufactures, and sells products
and devices that utilize its proprietary thermodynamic technology for the
processing of biological substances including the cryopreservation, thawing, and
harvesting of blood components. The Company was incorporated July 1986 as
InstaCool, Inc. of North America, and subsequently merged with Refrigeration
Systems International, Inc. In January of 1995, the Company changed its name to
the present to better reflect the thermodynamic blood-processing segment of the
biotechnology industry that it hopes to service through development of new
products.

Historically, THERMOGENESIS` primary revenues were from sales of ultra rapid
blood plasma freezers and thawers to hospitals, blood banks and blood transfusion
centers and plasma collection centers under US Food & Drug Administration
(FDA) clearance to market in the United States. During the fiscal years 1988
through 1995, the Company focused research and development efforts on the
refinement of product design for its blood plasma freezers and thawers. During that
period, the Company also sought new applications for its technology, including the
design of micro-manufacturing systems for biopharmaceutical drugs that utilize the
Company`s thermodynamic competence in new medical therapies.

Ultra Rapid Heat Freezers and Thawers

The Company`s Ultra Rapid freezers and thawers use heat transfer liquids, rather
than gases such as air, carbon dioxide or nitrogen to transfer heat to and from a
biological substance. The Company`s patented thin flexible plastic membrane
system is automatically interposed between the heat transfer liquid and the
container housing the blood component. Tests of the technology performed by the
Hague Center of the Netherlands Red Cross reports that 300 ml bags of plasma
were core frozen in 30 minutes versus 90-120 minutes in air blast freezers that
resulted in 18 to 32% more factor VIII in the cryoprecipitate from the frozen plasma.

In late Fiscal Year 1999, MP1100 MicroCascade, the first major upgrade of the
plasma freezer line was introduced. The MicroCascade is a breakthrough new
refrigeration technology that provides radically accelerated freezing performance.
The small, lightweight (100 lbs) integrated MicroCascade compressor/condenser
utilizing compact, lightweight Schroll compressors provides refrigeration capacity
equivalent to a bulky, heavy 8hp conventional remote compressor/condenser. The
advantage of the MicroCascade technology is that expensive and inflexible remote
condenser installations are not required. This flexibility allows laboratories to
quickly start up or modify their production routing by rolling in the MP1100,
plugging it into the electrical outlet and immediately begin flash freezing plasma.

Today, the Company still maintains the premier technology position in the plasma
freezing market segment, with competitors offering primarily 30-year-old blast
freezing (forced air) technology. A direct result of this advantage was the
Company`s success in establishing a significant market position in transfusion
societies and blood banks around the globe. The Company has five models of
freezers which vary primarily by capacity and condenser type. The MP 2000 and
MP 1000/1100 are suited for large laboratories running approximately 750 bags of
plasma per day. The MP 750 and MP 500 are suited for medium sized labs running
250 to 749 bags per day. The Company has three models of thawers. They vary
primarily by capacity: The MT202 thaws two bags simultaneously, and the MT204
and the MT210 four and ten bags respectively. In North America, the four major
manufacturers of plasma freezers are the Company, Revco, Forma Scientific and
Harris.

BioArchive Platform Products

The BioArchive Stem Cell System was the first product developed under the
BioArchive System technology platform. In collaboration with The NYBC, the
Company developed a disposable blood processing bag set that provides a sterile
method for collecting, concentrating and cryopreserving stem and progenitor cells
contained in PCB. These life giving stem and progenitor cells are targeted for
therapeutic use in patients who suffer from malignancies and genetic diseases of
the blood and immune system such as leukemia, lymphomas, diverse inherited
anemias, immunodeficiencies, acquired a plastic anemia and hypoproliferative
disorders.

The BioArchive Stem Cell System features a robotic cryogenic device that
automatically freezes, archives and manages an inventory of up to 3,626 PCB units
of stem and progenitor cells for transplant. The proprietary device also controls and
records the freezing profile of each PCB donation in nitrogen vapor, after which the
PCB unit is robotically transferred to a specified indexed location in liquid nitrogen.
The BioArchive System tracks the storage address of each PCB stem cell unit and
assures that only the specifically chosen, HLA matched PCB unit is retrieved when
selected for a human transplant recipient without exposing the other archived
samples to detrimental warming effects. The PCB stem and progenitor cell
donations are collected, processed, cryopreserved and transfused utilizing three
proprietary sterile disposable bag sets developed jointly by NYBC and the
Company and licensed to Medsep Corporation, a Division of Pall Corp., for
manufacturing and distribution in North America & Europe. The Company
re-acquired the rights to distribute the bag sets under its own name throughout the
rest of the world, except Japan.

In addition, the Company manufactures and sells three additional disposables
(canisters, canister sleeve, and overwrap bag) for the protection of the PCB units
during inter-laboratory transfers and shipment to the transplant centers which the
Company believes will provide an ongoing revenue stream.

The CryoSeal Platform products provide a superior and safer approach to producing
therapeutic doses of these proteins, enzymes and growth factors. Each CryoSeal
System is a micro-manufacturing platform which harvests and concentrates these
therapeutic blood components from the patient`s own blood, or in the case of such
medical conditions as hemophilia, from a directed donor.

MFG
Chali